|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.605 USD | +2.23% |
|
-1.52% | +14.54% |
| Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
| Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
The
The biotherapeutics company posted revenue of
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights.
, source
| 1st Jan change | Capi. | |
|---|---|---|
| +14.54% | 107M | |
| +2.28% | 42.75B | |
| +47.70% | 41.61B | |
| +11.79% | 41.34B | |
| -8.83% | 26.59B | |
| +6.53% | 25.49B | |
| -22.92% | 18.12B | |
| +30.28% | 12.24B | |
| -2.17% | 11.76B | |
| +9.14% | 11B |
ATYR PHARMA, INC. 
